Evogene Ltd. — Earnings Release 2026

May 20, 2026

5

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number: 001-36187

EVOGENE LTD.
(Translation of Registrant’s Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☑ Form 40-F ☐

---

CONTENTS

On May 20, 2026, Evogene Ltd. ("Evogene") announced its financial results for the first quarter ended March 31, 2026. A Copy of the press release announcing those results is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this "Form 6-K") and is incorporated herein by reference.

Evogene is holding a conference call on May 20, 2026 to discuss its quarterly results for the quarter ended March 31, 2026 and, in connection with that call, will make available to its investors a slide presentation to provide additional information regarding its business and its financial results. That slide presentation is attached as Exhibit 99.2 to this Form 6-K and is incorporated herein by reference.

The GAAP financial statements tables contained in the press release attached to this Form 6-K are incorporated by reference in the registration statements on Form F-3 (Securities and Exchange Commission ("SEC") File No. 333-277565), and Form S-8 (SEC File Nos. 333-193788, 333-201443, 333-203856, 333-259215, and 333-286197) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.
(Registrant)

Date: May 20, 2026

By: /s/ Ofer Haviv
Ofer Haviv
Chief Executive Officer

---

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	Press Release: Evogene Reports First Quarter 2026 Financial Results.
99.2	Slide presentation for conference call of Evogene held on May 20, 2026, discussing Evogene’s quarterly financial results for the first quarter of 2026.

---

evogene

Exhibit 99.1

Evogene Reports First Quarter 2026 Financial Results

Conference call and webcast: today, May 20, 2026, 9:00 AM ET

Rehovot, Israel – May 20, 2026 – Evogene Ltd. (Nasdaq, TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the first quarter ended March 31, 2026.

Mr. Ofer Haviv, President & CEO of Evogene, stated: “Following the strategic transformation initiated in 2025, we are now focused on execution and advancing our tech engine for small-molecule discovery and optimization, ChemPass AI™, and expanding our product pipeline in pharma and agriculture, through collaborations and continued progress in our internal programs.

ChemPass AI™’s competitive advantage lies in its ability to generate novel molecules while optimizing multiple critical parameters from the earliest stages of design. We continue to enhance the platform through internal development and collaboration with tech companies. In February 2026, we were proud to announce a second collaboration with Google Cloud focused on integrating advanced AI agents into ChemPass AI™, aimed at automating the generation of unique datasets from complex scientific workflows, thereby enabling new capabilities in small-molecule discovery and optimization.

Our proprietary small-molecule candidates are designed to combine three key advantages: novel and diverse chemical structures, multi-parameter optimization from the earliest design stages, and high potency supported by targeted experimental validation.

In pharma, we significantly expanded our activity during the first quarter of 2026, announcing three new collaborations with biotech companies and academic institutions:

• Systasy Biosciences, together with LMU University Hospital Munich. The collaboration focuses on developing novel therapies for neutrophil-derived inflammatory diseases;
• Queensland University of Technology (QUT). This collaboration is advancing AI-driven therapeutic discovery in inflammatory diseases and oncology; and
• Unravel Biosciences. This collaboration is focused on a newly discovered target for demyelinating disorders such as multiple sclerosis (MS).

These additions bring the total number of publicly disclosed collaborations in this domain to four.

In agriculture, our AgPlenus subsidiary continues to advance novel herbicide programs through our collaboration with Corteva. In parallel, our internal fungicide program has demonstrated strong progress and is advancing through lead optimization, highlighting the effectiveness of integrating AI-driven design with iterative experimental validation. Regarding our collaboration with Bayer, AgPlenus and Bayer have decided to discontinue their herbicide development project following determination that the target protein did not meet the required product criteria. Under the terms of the termination, all assets licensed to Bayer under the collaboration, including the APTH1 protein target and associated active molecules, will revert to AgPlenus.”

“Looking ahead, we expect continued progress across all three of the Company’s core business areas, supporting our growth trajectory and long-term value creation,” said Mr. Haviv. “We are expanding technological collaborations to strengthen our ChemPass AI™ innovation capabilities, advancing our pharmaceutical and ag-chemical pipelines toward key milestones, establishing new strategic partnerships, and deepening relationships with leading industry players. Across all activities, we remain focused on execution, pipeline expansion, and long-term growth.”

---

Financial Highlights:

• Status of Non-Core Subsidiaries - Consistent with our revised strategy, we continue to manage the wind-down or transition of our non-core business activities:

• Lavie Bio - operations were discontinued at the end of the first quarter of 2026, and the company expects to receive two additional payments under the ICL transaction. During the first quarter of 2026, Lavie Bio received court approval for the distribution of a dividend in the amount of $4.25 million to its shareholders, of which Evogene is entitled to approximately $2.9 million. The distribution process is expected to be completed in the second quarter of 2026.

• Biomica - licensed its lead oncology candidate, BMC128, to Lishan Pharmaceuticals and is currently completing a Phase 1 clinical trial. In April 2026, Biomica received court approval for the distribution of a $2.7 million dividend to its shareholders, of which Evogene will be entitled to approximately $1.35. The distribution process is expected to be completed in the second quarter of 2026.

• Casterra - operations have been significantly reduced and realigned to focus exclusively on Brazil; we are conducting field trials and expect these activities to form the basis for seed sales in the 2027 growing season.

• Fundraising - In February 2026, Evogene entered into a warrant inducement agreement with an existing investor for the immediate exercise of all August 2024 Series A and Series B warrants, resulting in gross proceeds of approximately $3.4 million, before fees and expenses. In consideration for the exercise, the investor received, in a private placement, new unregistered Series A-1 and Series B-1 warrants to purchase up to an aggregate of 5,076,924 ordinary shares. The new warrants are immediately exercisable at an exercise price of $1.25 per share.

The Series A-1 and Series B-1 warrants were classified as a liability in the consolidated statements of financial position, initially recorded at fair value and subsequently remeasured at each reporting date using the Black-Scholes option pricing model. As of March 31, 2026, the warrants' liability totaled approximately $1.7 million.

• Cash Position - As of March 31, 2026, Evogene held consolidated cash, cash equivalents, and short-term bank deposits of approximately $13.1 million. The consolidated cash usage during the first quarter of 2026 was approximately $2.8 million.

• Revenues for the first quarter of 2026 totaled approximately $0.3 million, compared to approximately $2.3 million in the same period of 2025, representing a decrease of approximately $2.0 million. The decrease is mainly attributable to lower revenue recognized from Casterra, which in the first quarter of 2025 included significant seed sales of approximately $2.0 million.

• Cost of revenues for the first quarter of 2026 was approximately $0.1 million, compared to approximately $1.5 million in the corresponding period of 2025. The decrease in cost of revenues is consistent with the decline in revenues during the quarter.

• Research and development expenses, net of non-refundable grants, for the first quarter of 2026 were approximately $1.8 million, compared to approximately $2.5 million in the corresponding period of 2025, representing a decrease of approximately $0.7 million. The decrease is mainly attributable to lower R&D expenses in Biomica, Casterra, and AgPlenus. The decrease in R&D expenses attributable to Evogene and its subsidiaries was substantially offset by the impact of exchange rate fluctuations between the U.S. dollar and the NIS of approximately $0.2 million.

• Sales and marketing expenses for the first quarters of 2026 and 2025 were approximately $0.4 million, with no material change between the periods.

• General and administrative expenses for the first quarter of 2026 remained stable at approximately $1.2 million, compared to the corresponding period of 2025. The decrease in G&A expenses attributable to Evogene and its subsidiaries was substantially offset primarily by the impact of transaction costs related to the warrant inducement transaction and other legal expenses, totaling approximately $0.2 million, as well as by exchange rate fluctuations between the U.S. dollar and the NIS of approximately $0.1 million.

• Other income, net, of approximately $30 thousand was recorded in the first quarter of 2026, primarily attributable to the sale of fixed assets, compared to other income of approximately $191 thousand recorded in the first quarter of 2025, which was primarily related to the accounting treatment associated with Evogene's sublease agreement.

• Operating loss for the first quarter of 2026 was approximately $3.2 million, compared to approximately $3.0 million in the corresponding period of 2025. The increase in operating loss is primarily attributable to decreased revenues, partially offset by lower operating expenses, as described above.

---

• Financing expenses, net, for the first quarter of 2026 were approximately $2.7 million, compared to financing income, net, of approximately $1.1 million in the corresponding period of 2025. The change was primarily attributable to the accounting treatment of the pre-funded warrants and warrants issued in the August 2024 fundraising and warrants issued in the February 2026 warrant inducement transaction. As part of the February 2026 warrant inducement transaction, the Company recorded financing expenses of approximately $3.8 million during the first quarter of 2026. In addition, the Company recorded a financing income of approximately $0.9 million related to the revaluation of warrants liability as of March 31, 2026.

• Income from discontinued operations, net, for the first quarter of 2026 was approximately $14 thousand, compared to a loss from discontinued operations, net, of approximately $1.1 million in the corresponding period of 2025. These amounts primarily reflect the financial results of Lavie Bio's operations, as well as expenses related to the development and maintenance of MicroBoost AI for Ag, which are presented as a single-line item in the consolidated statements of profit and loss. Following the sale of the majority of Lavie Bio's assets, as well as Evogene's MicroBoost AI for Ag, to ICL in July 2025, Lavie Bio no longer employs personnel, and its operating expense level has decreased significantly.

• Net loss for the first quarter of 2026 was approximately $5.9 million, compared to approximately $3.0 million in the same period last year. The increase of approximately $2.9 million was primarily attributable to a decrease in revenues and an increase in net financing expenses, partially offset by a decrease in operating expenses and a reduced loss from discontinued operations, net.

About Evogene Ltd.

Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and agchemical products.

At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.

For more information, please visit www.evogene.com.

---

Forward-Looking Statements

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates" or words of similar meaning. For example, Evogene is using forward-looking statements in this press release when it discusses Evogene's success in advancing its tech-engine for small-molecule discovery and optimization and expanding its product pipeline in pharma and agriculture, the success of Evogene's collaborations with biotech companies and academic institutions, the progress of AgPlenus' fungicide program, the expansion of technological collaborations, advancement of the Company's pharmaceutical and ag-chemical pipelines, establishment of new strategic partnerships, deeper relationships with leading industry players, and Casterra's seed sales in 2027 growing season. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene, including the aftermath of the recent war between Israel and each of (i) the terrorist groups, Hamas and Hezbollah, (ii) Iran, and (iii) other regional terrorist groups supported by Iran, and any destabilizations in Israel, neighboring territories or the Middle East region, as well as those additional risk factors identified in Evogene's reports filed with the applicable securities authority. In addition, Evogene relies, and expects to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Evogene Investor Relations Contact:

Email: ir@evogene.com

Tel: +972-8-9311901

---

CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

U.S. dollars in thousands

	March 31, 2026	December 31, 2025
	Unaudited
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$ 8,511	$ 12,956
Short-term bank deposits	4,543	-
Restricted cash	32	32
Trade receivables	286	317
Other receivables and prepaid expenses	1,416	1,565
Deferred expenses related to issuance of warrants	-	551
Inventories	175	210
	14,963	15,631
LONG-TERM ASSETS:
Long-term deposits and other receivables	576	571
Investment accounted for using the equity method	-	43
Deferred expenses related to issuance of warrants	-	1,165
Right-of-use-assets	1,672	1,824
Property, plant and equipment, net	737	812
	2,985	4,415
TOTAL ASSETS	$ 17,948	$ 20,046
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Trade payables	$ 463	$ 639
Employees and payroll accruals	922	861
Lease liabilities	654	716
Liabilities in respect of government grants	101	56
Deferred revenues and other advances	21	17
Warrants and pre-funded warrants liability	1,721	706
Other payables	1,482	449
	5,364	3,444
LONG-TERM LIABILITIES:
Lease liabilities	1,377	1,482
Liabilities in respect of government grants	3,149	3,073
Deferred revenues and other advances	68	72
	4,594	4,627
TOTAL LIABILITIES	$ 9,958	$ 8,071
SHAREHOLDERS' EQUITY:
Ordinary shares of NIS 0.2 par value:
Authorized – 30,000,000 ordinary shares; Issued and outstanding – 10,412,764 ordinary shares on March 31, 2026 and 6,672,173 ordinary shares on December 31, 2025	708	488
Share premium and other capital reserves	285,173	281,986
Accumulated deficit	(288,426)	(282,556)
Equity attributable to equity holders of the Company	(2,545)	(82)
Non-controlling interests	10,535	12,057
TOTAL EQUITY	7,990	11,975
TOTAL LIABILITIES AND EQUITY	$ 17,948	$ 20,046

---

---

---

CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS

U.S. dollars in thousands (except share and per share amounts)

	Three months ended March 31,		Year ended December 31,
	2026	2025(*)	2025
	Unaudited
Revenues	$ 334	$ 2,343	$ 3,853
Cost of revenues:
Inventory impairment	-	-	2,180
Other cost of revenues	130	1,517	1,914
Total Cost of Revenues	130	1,517	4,094
Gross profit	204	826	(241)
Operating expenses (income):
Research and development, net	1,839	2,471	7,994
Sales and marketing	389	397	1,476
General and administrative	1,156	1,176	4,286
Other expenses (income)	(30)	(191)	37
Total operating expenses, net	3,354	3,853	13,793
Operating loss	(3,150)	(3,027)	(14,034)
Financing income	1,171	1,584	2,508
Financing expenses	(3,884)	(458)	(1,933)
Financing income (expenses), net	(2,713)	1,126	575
Share of loss of an associate	43	2	39
Loss before taxes on income	(5,906)	(1,903)	(13,498)
Taxes on income	4	-	1
Loss from continuing operations	(5,910)	(1,903)	(13,499)
Income (loss) from discontinued operations, net	14	(1,086)	5,672
Loss	$(5,896)	$(2,989)	$(7,827)
Attributable to:
Equity holders of the Company	(5,870)	(2,587)	(8,485)
Non-controlling interests	(26)	(402)	658
	$(5,896)	$(2,989)	$(7,827)
Basic and diluted gain (loss) per share from continuing operations, attributable to equity holders of the Company	$(0.60)	$(0.26)	$(1.70)
Basic and diluted gain (loss) per share from discontinued operations, attributable to equity holders of the Company	$ 0.00	$(0.12)	$ 0.62
Basic and diluted gain (loss) per share, attributable to equity holders of the Company	$(0.60)	$(0.38)	$(1.08)
Weighted average number of shares used in computing basic and diluted loss per share	9,738,434	6,798,173	7,874,039

(*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.

---

CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

	Three months ended March 31,		Year ended December 31,
	2026	2025(*)	2025
	Unaudited
Cash flows from operating activities:
Loss from continuing operations	$ (5,910)	$ (1,903)	$ (13,499)
Adjustments to reconcile loss to net cash used in operating activities:
Adjustments to the profit or loss items:
Depreciation and amortization of property, plant and equipment and right-of-use-assets	202	310	1,144
Share-based compensation	(9)	238	654
Remeasurement of Convertible SAFE	-	-	(371)
Net financing income	(234)	8	(28)
Gain from sale of equipment and deduction of right-of-use asset and subsequent investment in sub-lease asset	(23)	(191)	(209)
Impairment of property, plant and equipment	-	-	246
Inventory impairment	-	-	2,180
Revaluation of government grants	20	-	40
Amortization of deferred expenses related to issuance of warrants	1,716	326	1,323
Expenses related to warrants inducement transaction	2,095	-	-
Remeasurement of pre-funded warrants and warrants	(1,046)	(1,477)	(1,781)
Share of loss of an associate	43	2	39
Taxes on income (tax benefit)	4	-	(6)
	2,768	(784)	3,231
Changes in asset and liability items:
Decrease (increase) in trade receivables	31	(1,530)	665
Decrease in other receivables and prepaid expenses	124	1,402	1,047
Decrease (increase) in inventories	35	(447)	(1,019)
Decrease in trade payables	(115)	(306)	(259)
Increase (decrease) in employees and payroll accruals	61	(227)	(756)
Decrease in other payables	(70)	(320)	(570)
Decrease in deferred revenues and other advances	-	(155)	(361)
	66	(1,583)	(1,253)
Cash received (paid) during the year for:
Interest received	137	95	338
Interest paid	(40)	(46)	(193)
Taxes paid	(15)	-	(11)
Net cash used in continuing operating activities	(2,994)	(4,221)	(11,387)
Net cash used in operating activities of discontinued operations	40	(961)	(2,115)
Net cash used in operating activities	(2,954)	(5,182)	(13,502)

---

CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

	Three months ended March 31,		Year ended December 31,
	2026	2025(*)
	Unaudited		2025
Cash flows from investing activities:
Purchase of property, plant and equipment	(2)	(121)	(135)
Proceeds from sale of property, plant and equipment	23	-	78
Proceeds from finance sub -lease asset	21	3	52
Withdrawal from (investment in) bank deposits, net	(4,528)	(2,327)	(1)
Net cash provided by (used in) continuing investing activities	(4,486)	(2,445)	(6)
Net cash provided by investing activities of discontinued operations	-	-	17,744
Net cash provided by investing activities	(4,486)	(2,445)	17,738
Cash flows from financing activities:
Proceeds from issuance of ordinary shares, net of issuance expenses	-	-	4,283
Proceeds from issuance of ordinary shares in warrant inducement transaction, net of issuance expenses	3,206	-	-
Repayment of lease liabilities	(121)	(146)	(526)
Proceeds from government grants	101	-	-
Dividend paid by subsidiary	(193)
Repayment of convertible SAFE	-	-	(10,000)
Repayment of government grants	-	(122)	(244)
Net cash provided by (used in) continuing financing activities	2,993	(268)	(6,487)
Net cash provided by (used in) financing activities of discontinued operations	-	109	(115)
Net cash provided by (used in) financing activities	2,993	(159)	(6,602)
Exchange rate differences - cash and cash equivalent balances	2	(20)	21
Increase (decrease) in cash and cash equivalents	(4,445)	(7,806)	(2,345)
Cash and cash equivalents at the beginning of the period	12,956	15,301	15,301
Cash and cash equivalents at the end of the period	$ 8,511	$ 7,495	$ 12,956
Significant non-cash activities
Acquisition of property, plant and equipment	-	-	2
Increase of right-of-use-asset recognized with corresponding lease liability	15	207	207
Exercise of pre-funded warrants	-	229	389
Derecognition of property, plant and equipment under a finance lease	-	13	13
Dividend declared by subsidiary but not yet paid	1,129	-	-

(*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.

---

Exhibit 99.2

evogene
REAL-WORLD PAYOUT CO.

EARNINGS CALL

Q1 2026

OFER HAVIV | PRESIDENT & CEO
May 20, 2026

---

FORWARD LOOKING STATEMENT

This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the "Company"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, pipeline, as well as our capabilities and technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the aftermath of the recent war between Israel and each of (i) the terrorist groups, Hamas and Hezbollah, (ii) Iran, and (iii) other regional terrorist groups supported by Iran, and any destabilizations in Israel, neighboring territories or the Middle East region, and those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

2 evogene

---

EARNINGS CALL Q1 2026

AGENDA

CEO UPDATE - By Ofer Haviv

VP FINANCE UPDATE - By Polina Ravzin

Q&A

3 evogene

---

EVOGENE PIONEERS REAL-WORLD INNOVATION

Using a proprietary generative AI engine, we design highly potent and novel small molecules, optimized across multiple-parameters, for the pharmaceutical and ag-chemical industries.

eVogene

---

Evogene – End Of 2025

PHARMA DIVISION –DRUGS

AG DIVISION* – AG-CHEMICALS

EXTERNAL COLLABORATIONS

EXTERNAL COLLABORATIONS

5 evogene

AG DIVISION* – Operations in this field are conducted through our subsidiary, AgPlenus.

---

Evogene Core Technology ChemPass AI - As Of Today (19.05.2026)

PHARMA DIVISION - DRUGS

AG DIVISION* - AG-CHEMICALS

Google Cloud

Second collaboration advanced AI agents integration

evogene

AG DIVISION* - Operations in this field are conducted through our subsidiary, AgPlenus.

---

7
eVogene

TECHNOLOGICAL COLLABORATIONS WITH GOOGLE CLOUD

FROM GENERATIVE MODELS TO AUTONOMOUS DISCOVERY

FIRST COLLABORATION – FIRST-IN-CLASS FOUNDATION MODEL

Successful completion of a proprietary generative AI model for novel molecular product candidates addressing multiple parameters, based on 38 billion molecular structures, delivered 90% precision compared to approx. 30% in traditional GPT models.

SECOND COLLABORATION – ADVANCED AI AGENTS INTEGRATION

Integration of AI agents into ChemPass AI™ using Google Cloud Vertex AI to decrease manual errors, accelerate design-make-test-analyze cycles, and enable scalable discovery of patentable small molecules with improved probability of development success for pharmaceutical and agricultural pipelines.

Initiated Feb. 2026

"This expanded collaboration with Evogene demonstrates the power of integrating cutting-edge artificial intelligence into scientific research. By leveraging our technology to deploy advanced AI agents, we are enabling Evogene to automate and scale their complex discovery workflows. This foundation accelerates the speed and precision of identifying small molecules, further cementing Evogene's role as a leader in next-generation molecular design for the pharmaceutical and agricultural industries"

BOAZ MAOZ, MANAGING DIRECTOR, GOOGLE CLOUD ISRAEL (10.02.2026)

Google Cloud

---

Evogene Pharma Division- As Of Today (19.05.2026)

PHARMA DIVISION – DRUGS

AG DIVISION* – AG-CHEMICALS

EXTERNAL COLLABORATIONS

systasy

Neutrophil-Derived

Inflammatory Diseases

UNRAVEL

BIO SCIENCES

Demyelination Disorders

GUT

Queensland

University

of Technology

Lung Cancer

TALARY THERETOSE

UNIVERSITY 234 01

Metabolic Disease

Google Cloud

Second collaboration

advanced AI agents integration

evoogene

AG DIVISION* – Operations in this field are conducted through our subsidiary, AgPlenus.

---

PHARMA DIVISION

COLLABORATION WITH SYSTASY BIOSCIENCE, LUDWIG MAXIMILIAN UNIVERSITY HOSPITAL, MUNICH, GERMANY

NOVEL THERAPIES FOR NEUTROPHIL-DERIVED INFLAMMATORY DISEASES

• Target: novel mechanism addressing large unmet needs in hyperinflammatory diseases such as inflammatory bowel disease (IBD).
• Addressable IBD market: valued at USD 20 billion in 2024, with projections approximately USD 33 billion by 2032*.
• Combines ChemPass AI™, Systasy's patient-derived functional validation systems, and LMU's leading clinical expertise.
• Funded by the prestigious EUREKA bi-national grant.

Target-Ligand complex

"This EUREKA-funded collaboration marks a pivotal step for Systasy in extending our PathwayProfiler platform to neutrophil biology. Partnering with Evogene's AI innovation, LMU's clinical expertise, and Weizmann's validation strengths positions us to deliver breakthrough therapies addressing unmet needs in hyper-inflammatory diseases. Our hyper-multiplexed, patient-derived assays will provide the high-quality functional data essential for accelerating discovery and ensuring translational success."

DR. SVEN WICHERT, CEO OF SYSTASY BIOSCIENCE (11.02.26)

evogene

https://www.glebeawareins.com/Trinness-wkann/2024/07/15/2913203-Wen-Inflammatory-Bowel-Disease-Treatment-Market-Site-Expected-to-Bunch-USB-23.19-06-by-2032.html

---

PHARMA DIVISION

COLLABORATION WITH UNRAVEL BIOSCIENCES, BOSTON, USA

NOVEL THERAPIES FOR DEMYELINATION DISORDERS

• Target: novel mechanism underlying neurodegenerative diseases.
• Focused on demyelinating diseases such as MS, representing a global market exceeding $28B*.
• Combines ChemPass AI™ with Unravel's patient-derived predictive biology technology to develop multi-parameter optimized therapies to improve neurological function.

Molecular modelling of putative modulator (green) in its target (surface in grey and interacting protein residues in colored spheres)

"We are thrilled to partner with Evogene to design an optimized new therapeutic candidates to promote remyelination for MS and other neurodegenerative disorders. The synergistic combination of Evogene's ChemPass AI™ platform and generative chemistry together with Unravel's patient RNA-derived Living Molecular Twins™ demonstrates the acceleration of drug development driven by novel data and advanced algorithms since patients cannot wait."

DR. RICHARD NOVAK, CEO OF UNRAVEL BIOSCIENCES (07.01.26)

10 evogene

• https://www.ebi.org.uk/environmental-issues/novel/impact/multiple-activities/biopsychosmics-nonfertilities/aroma-e-living-taxes

---

PHARMA DIVISION

COLLABORATION WITH DR. MARK ADAMS, QUT, BRISBANE, AUSTRALIA

NOVEL THERAPIES FOR CHEMOTHERAPY RESISTANCE IN CANCER TREATMENT

• Target: cellular mechanism responsible for resistance to cancer treatments.
• Global cancer drug resistance market is estimated at $5.4B in 2025*.
• Combines ChemPass AI™ with cutting edge cancer genomics to restore treatment sensitivity in resistant tumors.
• Designed to generate novel, brain-penetrant, small-molecule candidates addressing a major unmet need in oncology.

> "Partnering with Evogene is an exciting opportunity not only from a cell and molecular biology perspective, but also for its translational potential. Leveraging Evogene's AI-driven technology allows us to accelerate a path from research to real-world outcomes. By working together, I look forward to seeing our collective innovation one day make a meaningful difference for people living with cancer."
>
> DR. MARK ADAMS, PI, QUEENSLAND UNIVERSITY OF TECHNOLOGY (17.02.26)

Different ligands interact with distinct residues and occupy the pocket with diverse orientations

evogene

https://www.lifecenterbeauty.com/waan/14256247-cancer-drug-resistance-nucleoftehnocancer-clampdown

---

DIVERSIFIED SMALL MOLECULE PIPELINE (19.05.2026)

PROGRAM	INDICATION	HIT ID	HIT-TO-LEAD	LEAD OPTIMIZATION	PRE-CLINICAL	IND	PARTNER
EVGI110	Immunology						systasy
EVGN210	Neurology						UNRAVEL
BIOCHEMICALS
EVGO310	Oncology						Queensland University of Technology
EVGM410	Metabolism*						GOOD
UNIVERSITY OF TECHNOLOGY

• Non-protein target

12 evogene

---

EVOGENE – AS OF TODAY (19.05.2026)

PHARMA DIVISION – DRUGS

AG DIVISION* – AG-CHEMICALS

EXTERNAL COLLABORATIONS

systasy
Neutrophil-Derived
Inflammatory Diseases

UNRAVEL
BIO SCIENCES
Demyelination Disorders

GUT
Queensland
University
of Technology
Lung Cancer

TEL-AM® 214/877-2348
UNIVERSITY 2124 US

Metabolic Disease

EXTERNAL COLLABORATIONS

CORTEVA®
agriacience
Herbicides

INTERNAL PIPELINE
Wheat Blotch

13 evoGene
AG DIVISION* – Operations in this field are conducted through our subsidiary, AgPlenus.

---

agPlenus

EVREENC'S SUBSIDIARY

INTERNAL PIPELINE WHEAT BLOTCH

DISRUPTING A $1.28 PROBLEM AT RECORD SPEED

• 70% of EU fungicide usage in wheat is for Wheat Blotch¹
• EU market share >$1.28 annually¹
• Widespread resistance to current top products ('Strobilurins') with 2024 sales of $4.598²

APTF-1 PRESENTS STRONG POTENTIAL FOR REAL-WORLD INNOVATION

• Shows clear concentration-dependent antifungal efficacy
• Ongoing optimization to enhance potency
• 18 months from target to optimized hit

14

evogene

© Monocroft Summer 2017 © Global Growth Insights

---

END-TO-END PROCESS – NOVEL, HIGHLY POTENT, OPTIMIZED MOLECULES

WHEAT BLOTCH, DISRUPTING A $1.2B PROBLEM AT RECORD SPEED*

• 70% of EU fungicides are used for Wheat Blotch
• Widespread resistance to current products

TARGET PROTEIN

New MOA - no available crystallographic structure with limited computational data

• Performed by AgPlenus, Evogene's wholly owned subsidiary

15 evogene

---

DIVERSIFIED SMALL MOLECULE PIPELINE (19.05.2026)

PROGRAM	INDICATION	HIT ID	HIT-TO-LEAD	LEAD OPTIMIZATION	PRE-CLINICAL	IND	PARTNER
EVGI110	Immunology						systasy
EVGN210	Neurology						UNRAVEL
BIO SCIENCES
EVGO310	Oncology						GOOD
Queensland
University of Technology
EVGM410	Metabolism*						GOOD
WORLD
TECHNICAL SUITE

• Non-protein target

PROGRAM	INDICATION	HIT ID	HIT-TO-LEAD	LEAD OPTIMIZATION	SAFETY & ENVIRONMENT	FIELD TESTING	PARTNER
APCO-12	Herbicides	Stage confidential					CORTEVA
agricole
APTF1/APTF4	Fungicide						Internal

16 evogene

---

EVOGENE - LOOKING FORWARD

PHARMA DIVISION - DRUGS

• Progress in existing pipeline.
• New collaborations with biotech companies and academic institutions.
• Building relationships with pharmaceutical companies.
• Evaluation of projects for an internal pipeline.

Additional tech collaborations to maintain our competitive advantage

AG DIVISION* - AG-CHEMICALS

• Progress in existing pipeline.
• New collaborations with ag-chem companies.
• Evaluation of projects for expending internal pipeline.

17 evogene

AG DIVISION* – Operations in this field are conducted through our subsidiary, AgPlenus.

---

EARNINGS CALL Q1 2026

AGENDA

CEO UPDATE - By Ofer Haviv

VP FINANCE UPDATE - By Polina Ravzin

Q&A

18 evogene

---

EVOGENE SUBSIDIARIES' ACTIVITY

BIOMICA

lavie bio
better by nature

castera

19 evogene

---

EVOGENE SUBSIDIARIES' ACTIVITY

BIOMICA

Evogene and Shanghai Lishan
Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer

LISHAN BIOTECH

20 evogene

lavie bio

better by nature

Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL

ICL

---

EVOGENE SUBSIDIARIES' ACTIVITY

BIOMICA

lavie bio
better by nature

casterra

21 evogene

---

EVOGENE SUBSIDIARIES' ACTIVITY

casterra

• Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock.
• Casterra completed the 2026 planting of 13 trials across 7 Brazilian states: Bahia, Ceara, Goias, Maranhao, Mato Grosso, Minas Gerais, and Tocantins, covering most of Brazil's key castor-growing regions.

evogene

---

VP FINANCE UPDATE

FINANCIAL HIGHLIGHTS

CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

U.S. dollars in thousands

| | March 31, 2026
Unaudited | December 31, 2025 |
| --- | --- | --- |
| ASSETS | | |
| CURRENT ASSETS: | | |
| Cash and cash equivalents | $ 8,511 | $ 12,956 |
| Short-term bank deposits | 4,543 | - |
| Restricted cash | 32 | 32 |
| Trade receivables | 286 | 317 |
| Other receivables and prepaid expenses | 1,416 | 1,565 |
| Deferred expenses related to issuance of warrants | - | 551 |
| Inventories | 175 | 210 |
| | 14,963 | 15,631 |
| LONG-TERM ASSETS: | | |
| Long-term deposits and other receivables | 576 | 571 |
| Investment accounted for using the equity method | - | 43 |
| Deferred expenses related to issuance of warrants | - | 1,165 |
| Right-of-use-assets | 1,672 | 1,824 |
| Property, plant and equipment, net | 737 | 812 |
| | 2,985 | 4,415 |
| TOTAL ASSETS | $ 17,948 | $ 20,046 |

23 ev0gene

---

VP FINANCE UPDATE
FINANCIAL HIGHLIGHTS

| | March 31,
2026
Unaudited | December 31,
2025 |
| --- | --- | --- |
| CURRENT LIABILITIES: | | |
| Trade payables | $ 463 | $ 639 |
| Employees and payroll accruals | 922 | 861 |
| Lease liabilities | 654 | 716 |
| Liabilities in respect of government grants | 101 | 56 |
| Deferred revenues and other advances | 21 | 17 |
| Warrants and pre-funded warrants liability | 1,721 | 706 |
| Other payables | 1,482 | 449 |
| | 5,364 | 3,444 |
| LONG-TERM LIABILITIES: | | |
| Lease liabilities | 1,377 | 1,482 |
| Liabilities in respect of government grants | 3,149 | 3,073 |
| Deferred revenues and other advances | 68 | 72 |
| | 4,594 | 4,627 |
| TOTAL LIABILITIES | $ 9,958 | $ 8,071 |
| | | ☐ |
| SHAREHOLDERS' EQUITY: | | |
| Ordinary shares of NIS 0.2 par value:
Authorized – 30,000,000 ordinary shares; Issued and outstanding – 10,412,764 ordinary shares on March 31, 2026 and 6,672,173 ordinary shares on December 31, 2025 | 708 | 488 |
| Share premium and other capital reserves | 285,173 | 281,986 |
| Accumulated deficit | (288,426) | (282,556) |
| Equity attributable to equity holders of the Company | (2,545) | (82) |
| Non-controlling interests | 10,535 | 12,057 |
| TOTAL EQUITY | 7,990 | 11,975 |
| TOTAL LIABILITIES AND EQUITY | $ 17,948 | $ 20,046 |

evogene

---

VP FINANCE UPDATE
FINANCIAL HIGHLIGHTS

| | Three months ended
March 31, | | Year ended
December 31, |
| --- | --- | --- | --- |
| | 2026 | 2025 (*) | 2025 |
| | Unaudited | | |
| Revenues | $ 334 | $ 2,343 | $ 3,853 |
| Cost of revenues: | | | |
| Inventory impairment | - | - | 2,180 |
| Other cost of revenues | 130 | 1,517 | 1,914 |
| Total Cost of Revenues | 130 | 1,517 | 4,094 |
| Gross profit | 204 | 826 | (241) |
| Operating expenses (income): | | | |
| Research and development, net | 1,839 | 2,471 | 7,994 |
| Sales and marketing | 389 | 397 | 1,476 |
| General and administrative | 1,156 | 1,176 | 4,286 |
| Other(expenses (income)) | (30) | (191) | 37 |
| Total operating expenses, net | 3,354 | 3,853 | 13,793 |
| Operating loss | (3,150) | (3,027) | (14,034) |
| Financing income | 1,171 | 1,584 | 2,508 |
| Financing expenses | (3,884) | (458) | (1,933) |
| Financing income (expenses), net | (2,713) | 1,126 | 575 |
| Share of loss of an associate | 43 | 2 | 39 |
| Loss before taxes on income | (5,906) | (1,903) | (13,498) |
| Taxes on income | 4 | - | 1 |
| Loss from continuing operations | (5,910) | (1,903) | (13,499) |
| Income (loss) from discontinued operations, net | 14 | (1,086) | 5,672 |
| Loss | $ (5,896) | $ (2,989) | $ (7,827) |
| Attributable to: | | | |
| Equity holders of the Company | (5,870) | (2,587) | (8,485) |
| Non-controlling interests | (26) | (402) | 658 |
| | $ (5,896) | $ (2,989) | $ (7,827) |

25 ev0gene

---

EARNINGS CALL Q1 2026

AGENDA

CEO UPDATE - By Ofer Haviv

VP FINANCE UPDATE - By Polina Ravzin

Q&A

26 evogene

---

evogene

Creating
REAL-WORLD
INNOVATION
for a better future

THANK YOU